MariMed Inc. cultivates, produces, and dispenses medicinal and recreational cannabis in the U.S. and internationally. Key concerns include a low financial health score of 18/100, a negative net margin of -8.6%, and high debt-to-equity ratio of 2.01, indicating potential financial strain. However, the gross margin of 38.7% suggests some operational efficiency. The current ratio of 0.92 raises liquidity concerns, as it is below the ideal threshold of 1. Overall, while there are strengths in margins, the financial stability appears precarious.
Loading financial metrics...
Debt of $90.7M is 10.7x the company's cash position of $8.4M.
Gross profit margin decreased from 38.6% to 31.5% compared to last year.
Operating cash flow surged 365.1% YoY, indicating strong cash generation capability.
Free cash flow increased 365.1% YoY, enhancing capital allocation optionality.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q2 (June 30, 2026)